Literature DB >> 19111802

Optimizing outcomes at every stage of bladder cancer: do we practice it?

Harry Herr1, Badrinath Konety, John Stein, Cora N Sternberg, David P Wood.   

Abstract

Defining the best practices in treating any disease can lead to optimal treatment. Establishing these best practices is difficult, and relies on clinical trials, expert opinion, and consensus decisions. Bladder cancer is a heterogeneous disease that can be either relatively benign or highly malignant depending on the grade and stage of the tumor. Determining the best practices for bladder cancer is based on the stage, grade, and presentation of the cancer. Herein we identify four clinical scenarios involving bladder cancer and discuss whether best practice guidelines are available for these clinical scenarios, and if so, how often do we follow these guidelines.

Entities:  

Mesh:

Year:  2009        PMID: 19111802     DOI: 10.1016/j.urolonc.2008.06.005

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  5 in total

Review 1.  Maximizing cure for muscle-invasive bladder cancer: integration of surgery and chemotherapy.

Authors:  Andrew H Feifer; Jennifer M Taylor; Tatum V Tarin; Harry W Herr
Journal:  Eur Urol       Date:  2011-01-18       Impact factor: 20.096

2.  Patterns of care for early stage bladder cancer.

Authors:  Seth A Strope; Zaojun Ye; John M Hollingsworth; Brent K Hollenbeck
Journal:  Cancer       Date:  2010-06-01       Impact factor: 6.860

3.  Novel oncogenic function of mesoderm development candidate 1 and its regulation by MiR-574-3p in bladder cancer cell lines.

Authors:  Shuichi Tatarano; Takeshi Chiyomaru; Kazumori Kawakami; Hideki Enokida; Hirofumi Yoshino; Hideo Hidaka; Nijiro Nohata; Takeshi Yamasaki; Takenari Gotanda; Tokushi Tachiwada; Naohiko Seki; Masayuki Nakagawa
Journal:  Int J Oncol       Date:  2011-12-13       Impact factor: 5.650

4.  Surveillance and treatment of non-muscle-invasive bladder cancer in the USA.

Authors:  Daniel A Barocas; Denise R Globe; Danielle C Colayco; Ahunna Onyenwenyi; Amanda S Bruno; Thomas J Bramley; Rachel J Spear
Journal:  Adv Urol       Date:  2012-05-10

5.  ISO, via Upregulating MiR-137 Transcription, Inhibits GSK3β-HSP70-MMP-2 Axis, Resulting in Attenuating Urothelial Cancer Invasion.

Authors:  Xirui Guo; Haishan Huang; Honglei Jin; Jiheng Xu; Sanjiv Risal; Jingxia Li; Xin Li; Huiying Yan; Xingruo Zeng; Lei Xue; Changyan Chen; Chuanshu Huang
Journal:  Mol Ther Nucleic Acids       Date:  2018-07-04       Impact factor: 8.886

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.